- Home
- ETY vs AMRX Comparison
ETY vs AMRX Comparison
Compare ETY & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETY | AMRX |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ETY | AMRX |
|---|---|---|
| Price | $15.10 | $12.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 247.3K | ★ 1.8M |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 7.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $2,934,959,000.00 |
| Revenue This Year | N/A | $9.99 |
| Revenue Next Year | N/A | $6.67 |
| P/E Ratio | ★ N/A | $766.27 |
| Revenue Growth | N/A | ★ 9.50 |
| 52 Week Low | $10.59 | $6.69 |
| 52 Week High | $13.46 | $12.68 |
Technical Indicators
Market Signals| Indicator | ETY | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 60.32 |
| Support Level | $14.88 | $12.14 |
| Resistance Level | $15.77 | $12.53 |
| Average True Range (ATR) | 0.19 | 0.31 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 24.49 | 86.31 |
Price Performance
Historical ComparisonAbout ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.